Showing 4231-4240 of 5623 results for "".
- Market Scope: Global Refractive Market Rebounds Strongly After COVID-19https://modernod.com/news/market-scope-global-refractive-market-rebounds-strongly-after-covid-19/2480568/The impact of COVID-19 shutdowns initially sharply reduced the number of refractive surgical procedures, but demand has bounced back strongly, with the use of protec
- Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trials for Presbyopia and Dry Eye Diseasehttps://modernod.com/news/glaukos-announces-first-patient-enrolled-in-phase-2-clinical-trial-for-presbyopia/2480564/Glaukos announced that it has enrolled the first patient into a phase 2 clinical trial of GLK-302 for the treatment of presbyopia and GLK-301 for the treatment of signs and symptoms of dry eye disease (DED). GLK-302 is the second investigational drug candidate utilizing Glaukos&rsq
- Alcon Completes Acquisition of Ivantis, Bringing Hydrus Microstent into Its Global Surgical Portfoliohttps://modernod.com/news/alcon-completes-acquisition-of-ivantis-bringing-hydrus-microstent-into-its-global-surgical-portfolio/2480555/Alcon announced the closing of its previously announced acquisition of Ivantis, developer of the Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients in connection with cataract surge
- EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievementshttps://modernod.com/news/eyepoint-pharmaceuticals-announces-2022-clinical-plans-and-highlights-recent-corporate-and-clinical-achievements/2480554/EyePoint Pharmaceuticals announced its 2022 clinical pipeline plans and highlighted recent corporate achievements driven by its lead pipeline candidate, EYP-1901, a potential 6-month intravitreal treatment targeting wet age-related macular degeneration (AMD).
- Glaukos Announces FDA 510(k) Clearance of iPRIME Viscodelivery Systemhttps://modernod.com/news/glaukos-announces-fda-510k-clearance-of-iprime-viscodelivery-system/2480553/Glaukos announced that it has received 510(k) clearance from the FDA for the iPRIME Viscodelivery System, a sterile, single-use, minimally-invasive device for the delivery of viscoelastic fluid during ophthalmic surgery. “Since the introduction of our first&nb
- Using Cryo-Electron Tomography, UCI Researchers Reveal Molecular Mechanisms Underlying Mutations Within the Eye that Lead to Blindnesshttps://modernod.com/news/using-cryo-electron-tomography-uci-researchers-reveal-molecular-mechanisms-underlying-mutations-within-the-eye-that-lead-to-blindness/2480552/For the first time, University of California, Irvine researchers in collaboration with the Max-Planck Institute of Biochemistry, have revealed at a molecular level key structural determinants of the highly specialized rod outer segment (ROS) membrane architecture of the eye, which is instrum
- Kriya Expands Gene Therapy Pipeline and Establishes Its Rare Disease Therapeutic Area Division with Acquisition of Warden Biohttps://modernod.com/news/kriya-expands-gene-therapy-pipeline-and-establishes-its-rare-disease-therapeutic-area-division-with-the-acquisition-of-warden-bio/2480550/Gene therapy company Kriya Therapeutics announced that it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). Under the agreement, Kriya has obtained exclusive rights to Warden Bio’s five preclinical gene therapy programs.</
- Ray Therapeutics Closes $6M Seed Financing to Advance Novel Optogenetics Platform to Treat Blinding Diseaseshttps://modernod.com/news/ray-therapeutics-closes-6m-seed-financing-to-advance-novel-optogenetics-platform-to-treat-blinding-diseases/2480549/Ray Therapeutics, a developer of optogenetic gene therapies for patients with blinding diseases, announced the closing of a $6 million seed financing round, led by 4BIO Capital. The funding will be used to advance its optogenetic therapy, Ray-001, into clinical trials in retinitis
- EyeQue Launches MyReaderNumber App: Personalized Results for Reading and Computer Glasseshttps://modernod.com/news/eyeque-launches-myreadernumber-app-personalized-results-for-reading-and-computer-glasses/2480543/EyeQue introduced a first-of-its-kind smartphone app called MyReaderNumber that offers AR technology vision testing for presbyopia. EyeQue’s new AR-powered MyReaderNumber app delivers personalized measurements for both near reading distance and mid-distance (computer us
- New Survey From Bausch + Lomb and Glaucoma Research Foundation Reveals Emotional and Social Impact of Hyperemia on Glaucoma Patientshttps://modernod.com/news/new-survey-from-bausch-lomb-and-glaucoma-research-foundation-reveals-emotional-and-social-impact-of-hyperemia-on-glaucoma-patients/2480542/Bausch + Lomb and Glaucoma Research Foundation (GRF) released new key findings from a survey of glaucoma patients that was designed to gain a greater understanding of the impact that hyperemia can have in the treatment and lives of people living with glaucoma. In the Unit